Skip to content

The Effects of Massage Therapy on QOL in Youth/Young Adults With Cystic Fibrosis

The Effects of Massage Therapy on Quality of Life in Youth and Young Adults With Cystic Fibrosis: A Pilot Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01729585
Enrollment
30
Registered
2012-11-20
Start date
2013-07-31
Completion date
2015-03-31
Last updated
2015-09-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cystic Fibrosis, Quality of Life

Keywords

cystic fibrosis, quality of life

Brief summary

The purpose of this study is to describe the effects of massage therapy on quality of life (QOL) in youth and young adults (ages 8 to 21 years) with cystic fibrosis (CF).

Detailed description

Massage therapy (MT) is defined as hands on manipulation of the soft tissue of the body with the intent to produce therapeutic, physiologic effects and to promote health and well-being (Oawriter - OAC - codes.ohio.gov, 2010; American Massage Therapy Association, 2010). Quality of life is defined as a self-description (child or adult) or parent's description of the child's perceived health and well-being based on satisfaction with physical, emotional, psychosocial and school/role functioning (Varni et al., 2002). Additional measures for this study which may influence QOL include pain, pulmonary function, ease of breathing and thoracic excursion. Research Questions: i. What differences in changes of QOL scores, as measured by the Peds QL 4.0 (Pediatric Quality of Life Inventory) and the CFQ-R (Cystic Fibrosis Questionnaire - Revised) are found in youth and young adults with CF between the group receiving MT and control group? What changes in QOL scores in each group are found over time? ii. What differences in changes of musculoskeletal pain, as measured by the Numeric Rating Scale for pain are found in youth and young adults with CF between the group receiving MT and the control group? What changes in pain scores in each group are found over time? iii. What differences in changes of the pulmonary function are found in youth and young adults with CF between the group receiving MT and the control group in terms of the following: 1. Forced Expiratory Volume (FEV1) and Forced Vital Capacity (FVC) scores, 2. Single breath counting score, measuring ease of breathing, and 3. Thoracic excursion as measured by the cloth tape measure technique? What changes in the above pulmonary function in each group are found over time?

Interventions

PROCEDUREMassage Therapy

The Massage Therapy protocol consists of a series of 5 massages administered over 10 (+2) weeks. Length of time for each visit will be approximately 1.5 - 2 hours Typically, a series of treatments over time allows the body time to integrate tissue related changes and potentially maintain a more healthy musculoskeletal state. Based on expert opinion in the field of MT, following a series of massage treatments administered over time, one can anticipate tissue changes. By adding time between treatments, data will describe the ability of subjects to maintain changes over progressively longer periods of time. Treatment protocol will be based on the application of myofascial trigger point therapy (Timberlake, 1999) to musculoskeletal areas of the body often affected by disease progression in CF.

Sponsors

Children's Hospital Medical Center, Cincinnati
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
8 Years to 21 Years
Healthy volunteers
Yes

Inclusion criteria

Inclusion Criteria: * Diagnosis of CF evidenced by a prior documented positive sweat test (\>60 mEq/ml by quantitative pilocarpine iontophoresis and genotype with two identified mutations consistent with CF) * Males and females, aged 8 to 21 years at time of enrollment to obtain a broad range of symptoms related to tissue changes. (Over time, individuals with CF present with increasing symptoms with age and disease progression.) * English speaking * Pulmonary function clinical baseline \<100% (Baseline is defined as the highest PFT during the 6 months prior to PFT at enrollment.) \* This criteria was eliminated to expand eligible subjects (including PFT baseline \>100). * Clinically stable as defined by no evidence of acute upper or lower respiratory tract infections or other acute illnesses requiring use of antibiotics for at least 14 days prior to enrollment. (Pulmonary exacerbation often includes cough which may affect responses to MT.) \* this criteria was omitted after study began as subjects were frequently being treated with antibiotics secondary to CF and pulmonary exacerbations. * Approval to participate from Pulmonary Physician * Informed consent to participate

Exclusion criteria

* Exposed to any investigational drug or device within 30 days of enrollment * Any other illness at time of enrollment not a direct result of CF that the pulmonary physician determines that MT is contraindicated * Inability to lay flat on massage table as is required for massage protocol * Platelet count within past 12 months \< 100,000. (Contraindication for deep tissue MT.) \*eliminated this criteria with medical approval. * INR International Normalized Ratio (INR) - (blood test used to monitor the effectiveness of blood thinning drugs) within past 12 months \> 1.5 (Delayed clotting time is a contraindication for deep tissue MT.) \* eliminated this criteria with medical approval. * History of hepatosplenomegaly as deep tissue massage is contraindicated. * History of lung and/or liver transplant as deep tissue MT may be contraindicated with anti-rejection drug protocol. * Received MT within the past 30 days to eliminate the potential bias of previous response to treatment. \*changed protocol to allow enrollment and wait 30 days to initiate protocol. * Skin condition or injury that would be contraindicated for MT and would restrict ability to apply massage strokes according to protocol

Design outcomes

Primary

MeasureTime frameDescription
Quality of life _Peds QOL and CFQ-Rmeasured twice; visit 1 for baseline for treatment and control group and 10-12 weeks later following last treatment for treatment group, and same time frame for control groupstandardized measures of quality of life will be administered to subject and to parents of subjects under 18 years of age. Muscle tightness, ease of breathing, and overall relaxation 0-10 scores captured subjective QOL data.

Secondary

MeasureTime frameDescription
Pulmonary functionpre treatment, prior to each massage, post treatment; Time 1 = initial data collection; collect data over 10-12 weeks for treatment group. For control group, time 1 is initial data collection; time 2 is 10-12 weeks later.Pulmonary function test will be obtained prior to first data collection visit, using clinical pft's for treatment and control groups. Clinical pft's will also be obtained for control group 10-12 weeks following first data set. For treatment group, research pft will be obtained following last massage 10-12 weeks following initial data collection. Ease of breathing will be measured pre and post each massage for treatment group and at time 1 and 2 for control group. Thoracic excursion will be measured pre and post each massage and x2 during each massage for treatment group, and at time 1 and 2 for control group.

Other

MeasureTime frameDescription
Painat time 1, obtain baseline pain score. Collect pain score pre and post each massage and 1-2 days following each massage. control group pain scores wil be obtained following timeframe for post massage data collectionNumeric rating scale will be used to assess pain. Pain Location and NRS Pain Score \_\_Pre massage therapy \_\_Post massage therapy \_\_Follow-up phone call (date)\_\_\_\_\_ LOCATION OF PAIN NRS (0-10) Description of Pain (circle) Reported cause Start date Identify location and describe: sharp or dull; constant or intermittent Follow Up Phone Call for Pain Ask: Are you having pain? \_\_\_No \_\_\_Yes (If yes, ask the following questions and repeat for each location: Where is your pain? On a scale of 0 to 10, 0 being no pain and 10 the worst pain you have ever had, rate your pain in your (location). How would you describe your pain in your (location)? Is it sharp like a stabbing knife or dull like an ache or pressure? Is it constant (is it steady and does not change?) or is it intermittent (does it come and go)? What do you think caused you to have pain in your (location)? When did this pain start?

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026